PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Older ASCVD patients benefit from LDL-C lowering with evolocumab A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid

Latest News Updates

Steve Nissen Articles

Play

Lepodisiran: What progress towards Lp(a) reduction?

Lepodisiran: What progress towards Lp(a) reduction?

Lepodisiran (LY3819469) is a short interfering RNA (siRNA) targeted at the mRNA for apolipoprotein A (apoA) – an essential component of lipoprotein a (Lp(a)). Elevated levels of Lp(a) are associated with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis, and Lp(a) measurement is recommended at least…

Posted on 30 November 2023 | Posted by Steve Nissen | Posted in Expert views, Videos

Bempedoic acid: A CLEAR story

Bempedoic acid: A CLEAR story

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Steven Nissen

Posted on 19 October 2023 | Posted by Steve Nissen | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board

siRNA-mediated lowering of Lp(a) by SLN360

siRNA-mediated lowering of Lp(a) by SLN360

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Steve Nissen

Posted on 16 December 2022 | Posted by Steve Nissen | Posted in Hot topics, 17th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved